Quantitative determination of famotidine polymorphs: X-ray powder diffractometric and Raman spectrometric study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 49, Issue 2, 2009, Pages 338-346

  Német, Zoltán ^a   Kis, Gyozo Csonka ^a   Pokol, György ^b   Demeter, Ádám ^a  

^a GEDEON RICHTER LTD   (Hungary)

^b BUDAPEST UNIVERSITY OF TECHNOLOGY AND ECONOMICS   (Hungary)

Author keywords

Famotidine polymorphs; Multivariate calibration; Quantitative analysis; Raman spectrometry; X ray powder diffractometry

Indexed keywords

FAMOTIDINE;

ACCURACY; ANALYTIC METHOD; ARTICLE; CORRELATION ANALYSIS; DRUG STRUCTURE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAMAN SPECTROMETRY; UNIVARIATE ANALYSIS; X RAY POWDER DIFFRACTION;

ALGORITHMS; CALIBRATION; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; FAMOTIDINE; PARTICLE SIZE; POWDERS; REPRODUCIBILITY OF RESULTS; SPECTRUM ANALYSIS, RAMAN; STEREOISOMERISM; TECHNOLOGY, PHARMACEUTICAL; X-RAY DIFFRACTION;

EID: 59049090526     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2008.11.033     Document Type: Article

References (43)

1. Haleblian J.K., and McCrone W.C. J. Pharm. Sci. 58 (1969) 911-929
2. Raw A.S., Furness M.S., Gill D.S., Adams R.C., Holcombe Jr. F.O., and Yu L.X. Adv. Drug Deliv. Rev. 56 (2004) 397-414
3. Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry, ANDAs: Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information, June 2007, http://www.fda.gov/cder/guidance/index.htm.
4. Bernstein J. Polymorphism of Molecular Crystals (2002), Clarendon, Oxford
5. Federal Trade Commission, Generic Drug Entry Prior to Patent Expiration: An FTC Study, July 2002, http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf.
6. Threlfall T.L. Analyst 120 (1995) 2435-2460
7. In: Brittain H.G. (Ed). Polymorphism in Pharmaceutical Solids vol. 95 (1999), Marcel Dekker, New York
8. In: Zakrzewski A., and Zakrzewski M. (Eds). Solid State Characterization of Pharmaceuticals (2006), Assa International Inc., Danbury, Connecticut, USA
9. Klug H.P., and Alexander L.E. X-ray Diffraction Procedures for Polycrystalline and Amorphous Materials. 2nd edn. (1974), Wiley, New York
10. Suryanarayanan R. Pharm. Res. 6 (1989) 1017-1024
11. Suryanarayanan R., and Herman C.S. Pharm. Res. 8 (1991) 393-399
12. Bugay D.E., Newman A.W., and Findlay W.P. J. Pharm. Biomed. Anal. 15 (1996) 49-61
13. Black D.B., and Lovering E.G. J. Pharm. Pharmacol. 29 (1977) 684-687
14. Phadnis N.V., and Suryanarayanan R. Pharm. Res. 14 (1997) 1176-1180
15. Surana R., and Suryanarayanan R. Powder Diffr. 15 (2000) 2-6
16. Campbell Roberts S.N., Williams A.C., Grimsey I.A., and Booth S.W. J. Pharm. Biomed. Anal. 28 (2002) 1149-1159
17. Dong Z., Munson E.J., Schroeder S.A., Prakash I., and Grant D.J.W. Pharm. Res. 19 (2002) 1259-1264
18. Okumura T., and Otsuka M. J. Pharm. Sci. 94 (2005) 1013-1023
19. Iyengar S.S., Phadnis N.V., and Suryanarayanan R. Powder Diffr. 16 (2001) 20-24
20. Uvarov V., and Popov I. J. Pharm. Biomed. Anal. 46 (2008) 676-682
21. Dong W., Gilmore C., Barr G., Dallman C., Feeder N., and Terry S. J. Pharm. Sci. 97 (2008) 2260-2276
22. Pelletier M.J. Appl. Spectrosc. 57 (2003) 20A-42A
23. Bugay D.E. Adv. Drug Deliv. Rev. 48 (2001) 43-65
24. Stephenson G.A., Forbes R.A., and Reutzel-Edens S.-M. Adv. Drug Deliv. Rev. 48 (2001) 67-90
25. Kontoyannis C.G., Bouropoulos C.Ch., and Koutsoukos P.G. Appl. Spectrosc. 51 (1997) 64-67
26. Langkilde F.W., Sjöblom J., Tekensberg-Hjelte L., and Mrak J. J. Pharm. Biomed. Anal. 15 (1997) 687-696
27. Taylor L.S., and Zografi G. Pharm. Res. 15 (1998) 755-761
28. Al-Zoubi N., Koundourellis J.E., and Malamataris S. J. Pharm. Biomed. Anal. 29 (2002) 459-467
29. Campbell Roberts S.N., Williams A.C., Grimsey I.M., and Booth S.W. J. Pharm. Biomed. Anal. 28 (2002) 1135-1147
30. Deeley C.M., Spragg R.A., and Threlfall T.L. Spectrochim. Acta 47A (1991) 1217-1223
31. Tudor A.M., Church S.J., Hendra P.J., Davies M.C., and Melia C.D. Pharm. Res. 10 (1993) 1772-1776
32. Jalsovszky G., Egyed O., Holly S., and Hegedu{combining double acute accent}s B. Appl. Spectrosc. 49 (1995) 1142-1145
33. Pratiwi D., Fawcett J.P., Gordon K.C., and Rades T. Eur. J. Pharm. Biopharm. 54 (2002) 337-341
34. Strachan C.J., Pratiwi D., Gordon K.C., and Rades T. J. Raman Spectrosc. 35 (2004) 347-352
35. De Spiegeleer B., Baert B., Diericx N., Seghers D., Verpoort F., Van Vooren L., Burvenich C., and Slegers G. J. Pharm. Biomed. Anal. 44 (2007) 254-257
36. Hegedu{combining double acute accent}s B., Bod P., Harsányi K., Péter I., Kálmán A., and Párkányi L. J. Pharm. Biomed. Anal. 7 (1989) 563-569
37. Ferenczy G., Párkányi L., Ángyán J.G., Kálmán A., and Hegedu{combining double acute accent}s B. J. Mol. Struct. (Theochem.) 503 (2000) 73-79
38. Német Z., Hegedu{combining double acute accent}s B., Szántay Jr. Cs., Sztatisz J., and Pokol G. Thermochim. Acta 430 (2005) 35-41
39. Tian F., Zhang F., Sandler N., Gordon K.C., McGovering C.M., Strachan C.J., Saville D.J., and Rades T. Eur. J. Pharm. Biopharm. 66 (2007) 466-474
40. Német Z., Demeter A., and Pokol G. J. Pharm. Biomed. Anal. 49 (2009) 32-41
41. Hurst V.J., Schroeder P.A., and Styron R.W. Anal. Chim. Acta 337 (1997) 233-252
42. Brittain H.G. J. Pharm. Sci. 91 (2002) 1573-1580
43. Food and Drug Administration, Center for Drug Evaluation and Research, Guidance for Industry, ICH Topic Q2B. Validation of Analytical Procedures: Methodology, November 1996, http://www.fda.gov/cder/Guidance/1320fnl.pdf.